Read the analysis: Michael Weintraub, MD Neil Iyengar Stephen Nicholls To view or add a comment, sign in This paper is a great reminder that CAD is not a binary disease, and neither is risk
For example, while about 86.4% of participants in major semaglutide trials achieved at least a 5% weight reduction, your journey will reflect your own bodys timeline
Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes
The most common side effects include nausea (44% of patients), diarrhea (30%), vomiting (24%), and constipation (24%), according to the Wegovy prescribing information
In a recent review published in the Journal of Clinical and Translational Hepatology , researchers explore the therapeutic potential and clinical insights of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the management of metabolic dysfunction-associated steatotic liver disease (MASLD)